Overview

This trial is active, not recruiting.

Conditions glioblastoma, gliomas
Treatments temozolomide
Phase phase 2
Sponsor Memorial Sloan-Kettering Cancer Center
Collaborator Schering-Plough
Start date August 2005
End date August 2014
Trial size 140 participants
Trial identifier NCT00200161, 05-079

Summary

Patients have a newly diagnosed brain tumor called a malignant glioma and participate in the study to see if it is possible to increase the benefit of temozolomide when given after radiation. A recent study showed that patients with newly diagnosed glioblastoma lived longer when treated with both temozolomide and radiotherapy followed by 6 months of temozolomide than patients treated with radiotherapy alone. Patients will receive standard low dose temozolomide during radiation. After radiation, they will be randomized to receive either more intense temozolomide or continuous low dose temozolomide.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
temozolomide
Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
(Experimental)
Concurrent temozolomide and radiotherapy plus high dose of temozolomide
temozolomide
Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.

Primary Outcomes

Measure
To determine the overall survival of patients with newly diagnosed glioblastoma multiforme treated with concurrent temozolomide and radiotherapy followed by dose dense or metronomic dosing of temozolomide and maintenance cis-retinoic acid.
time frame: until death or date of last follow up

Secondary Outcomes

Measure
Progression free survival
time frame: until tumor progression
To evaluate the prognostic impact of methylated MGMT status.
time frame: at the end of study
To collect preliminary data on the efficacy of this regimen and impact of MGMT status in other malignant glioma subtypes.
time frame: at the end of study

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Pathologic evidence of a malignant glioma. - Tissue block or unstained slides must be available for MGMT analysis. - Age 18-70 - KPS > 50 - Granulocyte count >1.5 X 109/L - Platelet count >99 X 109/L - SGOT < 2.5X upper limit of normal (ULN). - Serum creatinine < 2X ULN. - Bilirubin < 2X ULN. - All patients must sign written informed consent. Exclusion Criteria: - Any prior chemotherapy, radiotherapy and biologic therapy for glioma. - Any prior experimental therapy for glioma. - Other concurrent active malignancy (with the exception of cervical carcinoma in situ or basal cell ca of the skin). - Serious medical or psychiatric illness that would in the opinion of the investigator would interfere with the prescribed treatment. - Pregnant or breast feeding women. - Refusal to use effective contraception.

Additional Information

Official title A Randomized Phase II Trial of Concurrent Temozolomide and Radiotherapy Followed by Dose Dense Versus Metronomic Temozolomide and Maintenance Cis-Retinoic Acid for Patients With Newly Diagnosed Glioblastoma and Other Malignant Gliomas
Principal investigator Lisa DeAngelis, M.D
Description This is a randomized phase II study that will test two different adjuvant temozolomide regimens in patients with newly diagnosed glioblastoma multiforme. The goal of this study is to identify a regimen that would be appropriate to bring to a phase III trial and compare to the standard dosing regimen of temozolomide recently reported by Stupp et al. in the New England Journal of Medicine. Secondary goals of this study include: prospective analysis of the prognostic impact of MGMT status and generation of preliminary data regarding this treatment strategy for other types of malignant glioma. The decision regarding which treatment patients receive is made randomly. Neither them or their doctor can select which treatment the patient will receive. There is reason to believe that both of these doses may benefit treating your brain tumor. After 6 months of chemotherapy, and assuming the brain tumor has not shown any sign of growth, they will begin receiving cis-retinoic acid. Cis retinoic acid has been shown in one study to possibly prevent or delay tumor recurrence.
Trial information was received from ClinicalTrials.gov and was last updated in November 2013.
Information provided to ClinicalTrials.gov by Memorial Sloan-Kettering Cancer Center.